California's StemCells, Inc., Flatlines; A Look at the Implications
By David Jensen,
California Stem Cell Report
| 06. 01. 2016
Untitled Document
Highlights
Layoffs, clinical trial closed
Conflicts of interest
Implications for CIRM
Risk and stem cell research
Twenty years ago, StemCells, Inc., was more than riding high. Its stock price (split adjusted) had skyrocketed to $2,160 in January of 1996. Its outlook was ebullient. But times have changed. Today the company's stock plummeted as low as 51 cents after it announced that it was closing its doors.
The company said yesterday that it is possible that its shareholders will wind up with nothing. Its 50 employees will lose their jobs this summer. And its latest clinical trial for spinal cord injury has been cancelled because the results do not merit spending any more money.
The company's sudden shutdown surprised and shocked some, but it also demonstrated the level of risk in stem cell research and offered implications for California's $3 billion stem cell agency, which is pushing aggressively to bring a stem cell therapy to market.
StemCells, Inc., was co-founded by two respected academic stem cell researchers, Irv Weissman of Stanford, and Fred Gage of the Scripps...
Related Articles
By Aileen Editha, The Conversation | 12.11.2024
By Staff, Reuters | 12.04.2024
The Centers for Medicare & Medicaid Services said on Wednesday it had entered into agreements with Vertex Pharmaceuticals (VRTX.O), opens new tab and bluebird bio (BLUE.O), opens new tab to help increase patient access to their gene therapies.
The so-called...
By Staff, Center for Food Safety | 12.03.2024
Photo by Markus Winkler on Unsplash
SAN FRANCISCO—In a precedential victory for food and environmental safety, a federal district court ruled today that genetically engineered (GE) organisms must be regulated. The Court's ruling overturns the 2020 rule overhaul by the...
Image by Mohamed Hassan from Pixabay
It is hard to make predictions, especially about the future, as Yogi Berra, Niels Bohr, and other luminaries have remarked. But there are already signs that the incoming Trump administration may have some difficulty establishing consistent policies about controversial issues concerning human reproduction.
On the one hand, consider “the conservative blueprint for a second Trump administration.”
The notorious Project 2025’s Mandate for Leadership seeks to delete terms such as “reproductive rights” from “every federal...
